Attributes | Values |
---|
rdf:type
| |
description
| - assaig clínic (ca)
- clinical trial (en)
- clinical trial (en-ca)
- clinical trial (en-gb)
- clinical trial (en-us)
- ensaio clínico (gl)
- ensayo clínico (es)
- ensayu clínicu (ast)
- essai clinique (fr)
- klinisch onderzoek (nl)
- клінічне випробування (uk)
|
rdfs:label
| - Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate (en)
- Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate (nl)
|
skos:prefLabel
| - Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate (en)
- Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate (nl)
|
name
| - Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate (en)
- Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate (nl)
|
title
| |
title
| - A Phase II, Randomized, Double-Blind Study to Evaluate the Effects of MEDI-522, a Humanized MAb to Integrin Alpha V Beta 3, On Disease Activity and Progression of Joint Damage in Pts With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate (en)
|
instance of
| |
instance of
| |
start time
| |
start time
| |
country
| |
country
| |
research site
| |
research site
| |
minimum age
| |
minimum age
| |
medical condition
| |
medical condition
| |
number of participants
| |
number of participants
| |
study type
| |
study type
| |
ClinicalTrials.gov ID
| |
ClinicalTrials.gov ID
| |
clinical trial phase
| |
clinical trial phase
| |
is about
of | |